Salvianolic acid A suppresses CCL-20 expression in TNF-α-treated macrophages and ApoE-deficient mice

J Cardiovasc Pharmacol. 2014 Oct;64(4):318-25. doi: 10.1097/FJC.0000000000000117.

Abstract

Objectives: The CC chemokine ligand-20 (CCL-20)/macrophage inflammatory protein-3α has been seen as one of the most important chemokines and played a key role in atherogenesis, but the mechanism that underlies the regulation of CCL-20 has not been established clearly yet. The aim of this study was to investigate the influence of salvianolic acid A (SAA) on the expression of CCL-20 in macrophages and ApoE-deficient (ApoE) mice.

Methods: The expression of CCL-20 was detected both at protein and messenger RNA levels in RAW264.7 cells. We validated the result in ApoE mice that were intraperitoneally injected with SAA. Phosphorylation of p38 mitogen-activated protein kinase was detected with Western blot, and inhibitor of p38 was used to investigate the mechanism of regulation of CCL-20. Hematoxylin and eosin and Oil-Red-O staining were used to evaluate the atherosclerotic lesions and lipid accumulation in ApoE mice. Immunohistochemical analysis was used to detect the expressions of CCL-20 and CCR6 in the atherosclerotic lesions. Immunofluorescent analysis was used to certify the origination of CCL-20.

Results: Recombinant tumor necrosis factor-α (TNF-α) upregulated CCL-20 production in dose- and time-dependent manners in RAW264.7 cells. The activity of TNF-α-induced CCL-20 production seemed to be significantly suppressed by SAA. Using p38 mitogen-activated protein kinase inhibitor, we found that p38 mediated the effects of TNF-α- and SAA-induced CCL-20 expression changes. In addition, immunohistochemical analysis of aortic root of ApoE mice also demonstrated that the expressions of CCL-20 and CCR6 were both downregulated significantly with SAA treatment. Furthermore, treatment of SAA inhibited the progression of the atherosclerotic plaques and lipid accumulation.

Conclusions: These results demonstrate that TNF-α increased but SAA suppressed CCL-20 production significantly via a novel mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / genetics
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Blotting, Western
  • Caffeic Acids / pharmacology*
  • Cell Line
  • Chemokine CCL20 / genetics*
  • Chemokine CCL20 / immunology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Lactates / pharmacology*
  • Lipid Metabolism / drug effects
  • Macrophages / drug effects*
  • Macrophages / immunology
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Real-Time Polymerase Chain Reaction
  • Recombinant Proteins
  • Sinus of Valsalva / drug effects
  • Sinus of Valsalva / metabolism
  • Sinus of Valsalva / pathology
  • Time Factors
  • Tumor Necrosis Factor-alpha / immunology
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Up-Regulation

Substances

  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • CCL20 protein, mouse
  • Caffeic Acids
  • Chemokine CCL20
  • Lactates
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • salvianolic acid A